pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,455 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1888Endpoints1464Fierce Biotech779BioSpace767BioPharma Dive554raps254onclive165fda recalls122
therapy area
allOncology13092Rare Disease3386Immunology3069Cardiology2865Hematology2334Pulmonology2297Vaccines
  • Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trial
    Helus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…
    Fierce Biotech · 4d agoPositive readoutPositive↗ source
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 4d agoDealPositive↗ source
← prev
page 3 of 59
next →
fda medwatch116
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseases
    Biogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
    Fierce Biotech · 4d agoDealPositive↗ source
  • AriBio’s oral Alzheimer’s candidate shows significant benefit in monotherapy subgroup in phase 3 trial
    AriBio’s AR1001, an oral PDE5 inhibitor originally developed for erectile dysfunction, is being tested as a treatment for early Alzheimer’s disease. In the global phase 3 Polaris-AD trial, the dru…
    Fierce Biotech · 3d agoPositive readoutNeutral↗ source
  • Sellas vaccine shows 9-month overall survival gain in phase 3 AML trial
    Sellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…
    Fierce Biotech · 3d agoPositive readoutPositive↗ source
  • FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancer
    Summit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
    BioPharma Dive · 4d agoRegulatoryNegative↗ source
  • J&J to acquire Ollin Biosciences for up to $3.3 billion, adding eye disease drug to its portfolio
    Johnson & Johnson announced it will purchase Ollin Biosciences, a biotechnology startup developing an eye disease therapy. The transaction includes an upfront payment of $2.2 billion and up to $1.…
    BioPharma Dive · 4d agoDealPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancers
    Eli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
    BioPharma Dive · 4d agoDealPositive↗ source
  • CG Oncology reports 68% drop in bladder cancer recurrence in phase 3 trial of cretostimogene
    CG Oncology announced results from a phase 3 study of its oncolytic virus immunotherapy, cretostimogene, in patients with non-muscle invasive bladder cancer after surgery. The trial, involving 367…
    Fierce Biotech · 4d agoPositive readoutPositive↗ source
  • Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug Discoveries
    Scientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…
    BioPharma Dive · 4d agoNeutral↗ source
  • Clinical AI pilots stall due to organizational environment, not technology
    Clinical teams are increasingly using artificial intelligence to draft regulatory paperwork, assist data review, shape trial design and interpret complex evidence. The technology is proving its val…
    BioPharma Dive · 4d agoNeutral↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi
    Seawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…
    BioPharma Dive · 4d agoDealPositive↗ source
  • Flagship Pioneering invests £100 million to launch AI-focused biotech incubation lab in London
    Flagship Pioneering announced a £100 million investment to establish its first AI-focused biotech incubation unit outside Cambridge, locating it in London. The new Flagship Origination Lab, U.K.,…
    Fierce Biotech · 4d agoDealPositive↗ source
  • Study finds plastic particles in brains of dementia patients, prompting re-evaluation of disease theories
    Researchers at the University of New Mexico reported the presence of microscopic plastic deposits surrounding blood vessels in the brains of individuals who died from dementia. The findings were pr…
    Fierce Biotech · 3d agoNeutral↗ source
  • Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firms
    Sofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
    BioPharma Dive · 4d agoDealPositive↗ source
  • Chinese authorities dismiss two researchers after child dies in gene‑editing study
    Chinese authorities have dismissed two researchers involved in a gene‑editing study after a child participant died. State media reported the firings, showing the government's swift response to the…
    Fierce Biotech · 4d agoRegulatoryNegative↗ source
  • Tandem Diabetes Care gets FDA clearance for tubeless insulin delivery system with up to 7-day wear
    Tandem Diabetes Care announced that the FDA has cleared its Tandem Mobi system as a tubeless automated insulin delivery device. The clearance allows the device to be worn for up to seven days witho…
    Fierce Biotech · 4d agoRegulatoryPositive↗ source
  • New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
    Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
    BioPharma Dive · 4d agoPositive↗ source
  • Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program dropped
    Aclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…
    Fierce Biotech · 4d agoNegative readoutNegative↗ source
  • Naia Inc. recalls Chocolate Banana Bar Sorbetto over undeclared milk, egg and pistachio allergens
    Naia Inc., based in Hercules, California, announced a recall of its Chocolate Banana Bar Sorbetto. The recall applies to bars bearing the code dates "BB:Oct/05/2027", "BB:Oct/06/2027", "BB:Oct/07/…
    fda recalls · 4d agoCRLNegative↗ source
  • ALDI recalls Priano protein tortelloni over possible Clostridium botulinum contamination
    ALDI of Batavia, Illinois announced on November 16, 2026 that it is recalling its Priano Protein Carbonara Tortelloni and Priano Protein Herb & Cheese Tortelloni sold at select stores in Alabama, G…
    fda recalls · 4d agoRegulatoryNegative↗ source
  • Medline recalls all brand beds, rails, mattresses and accessories over fire and entrapment risk
    Medline announced a recall of its entire line of Medline Brand beds, rails, mattresses and related accessories in the United States and Canada. The recall, launched on October 14, 2026, cites a po…
    fda recalls · 6d agoCRLNegative↗ source
  • FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer
    The U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…
    Fierce Biotech · 7d agoRegulatoryNegative↗ source
  • Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapy
    Novo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
    BioPharma Dive · 7d agoApprovalPositive↗ source
  • Neuroscience startups attract $450M in recent funding, Oyster Therapeutics secures $60M Series A
    Venture capital activity around neuroscience has picked up again, with five neurology-focused startups collectively raising about $450 million in the past few weeks. Data from BioPharma Dive show…
    BioPharma Dive · 7d agoDealPositive↗ source